Business Description
Acumen Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00509G2093
Description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 9.03 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -0.53 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -56.7 | |||||
3-Year EPS without NRI Growth Rate | -56.2 | |||||
3-Year FCF Growth Rate | -50.5 | |||||
Future 3-5Y EPS without NRI Growth Rate | -17.18 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 86.93 | |||||
9-Day RSI | 73.21 | |||||
14-Day RSI | 62.41 | |||||
6-1 Month Momentum % | -31.96 | |||||
12-1 Month Momentum % | -57.96 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 30.2 | |||||
Quick Ratio | 30.2 | |||||
Cash Ratio | 29.81 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.1 | |||||
Shareholder Yield % | -12.94 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -24.17 | |||||
ROA % | -22.15 | |||||
ROIC % | -126.56 | |||||
ROC (Joel Greenblatt) % | -17733.96 | |||||
ROCE % | -21.57 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.7 | |||||
Price-to-Tangible-Book | 0.7 | |||||
EV-to-EBIT | 0.93 | |||||
EV-to-Forward-EBIT | -0.06 | |||||
EV-to-EBITDA | 0.94 | |||||
EV-to-Forward-EBITDA | -0.06 | |||||
EV-to-FCF | 1.09 | |||||
Price-to-Net-Current-Asset-Value | 0.84 | |||||
Price-to-Net-Cash | 0.86 | |||||
Earnings Yield (Greenblatt) % | 107.53 | |||||
FCF Yield % | -27.79 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ABOS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Acumen Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -1.06 | ||
Beta | 0.09 | ||
Volatility % | 123.74 | ||
14-Day RSI | 62.41 | ||
14-Day ATR ($) | 0.194241 | ||
20-Day SMA ($) | 2.39275 | ||
12-1 Month Momentum % | -57.96 | ||
52-Week Range ($) | 1.8101 - 11.3099 | ||
Shares Outstanding (Mil) | 60.08 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Acumen Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Acumen Pharmaceuticals Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Acumen Pharmaceuticals Inc Frequently Asked Questions
What is Acumen Pharmaceuticals Inc(ABOS)'s stock price today?
The current price of ABOS is $3.04. The 52 week high of ABOS is $11.31 and 52 week low is $1.81.
When is next earnings date of Acumen Pharmaceuticals Inc(ABOS)?
The next earnings date of Acumen Pharmaceuticals Inc(ABOS) is 2024-08-08 Est..
Does Acumen Pharmaceuticals Inc(ABOS) pay dividends? If so, how much?
Acumen Pharmaceuticals Inc(ABOS) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |